1. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency
- Author
-
Yingxia Xu, Shin-San Michael Su, Zhiwei Gu, Scott A. Biller, Charles Kung, Xiaobing Lv, Cheng Fang, Collin Hill, Yaguang Si, Zhiyong Luo, Penelope A. Kosinski, Francesco G. Salituro, Lenny Dang, Huachun Tang, Hua Yang, Lee Silverman, Kendall Johnson, Janeta Popovici-Muller, Gui Yao, Jeff Hixon, Gavin Histen, Stefan Gross, Yue Chen, Byron DeLaBarre, and Giovanni Cianchetta
- Subjects
Hemolytic anemia ,Erythrocytes ,Anemia ,Immunology ,Allosteric regulation ,Pyruvate Kinase ,Enzyme Activators ,Pharmacology ,Biology ,Pyruvate Metabolism, Inborn Errors ,Biochemistry ,Piperazines ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Red Cells, Iron, and Erythropoiesis ,medicine ,Animals ,Humans ,Glycolysis ,chemistry.chemical_classification ,Sulfonamides ,Cell Biology ,Hematology ,Anemia, Hemolytic, Congenital Nonspherocytic ,medicine.disease ,Molecular biology ,Recombinant Proteins ,Tissue Donors ,Enzyme Activation ,Kinetics ,Enzyme ,chemistry ,030220 oncology & carcinogenesis ,Quinolines ,Pyruvate kinase ,Ex vivo ,030215 immunology ,Pyruvate kinase deficiency - Abstract
Pyruvate kinase (PK) deficiency is a rare genetic disease that causes chronic hemolytic anemia. There are currently no targeted therapies for PK deficiency. Here, we describe the identification and characterization of AG-348, an allosteric activator of PK that is currently in clinical trials for the treatment of PK deficiency. We demonstrate that AG-348 can increase the activity of wild-type and mutant PK enzymes in biochemical assays and in patient red blood cells treated ex vivo. These data illustrate the potential for AG-348 to restore the glycolytic pathway activity in patients with PK deficiency and ultimately lead to clinical benefit.
- Published
- 2017